Methotrexate Subcutaneous 22.5 mg (Methotrexate (Methotrexate Sodium) SOLUTION) 22.5 MG

Methotrexate Subcutaneous 22.5 mg is a solution used for various medical conditions. This medication is administered subcutaneously and is known for its effectiveness in targeted therapy.

Strength

22.5 MG

Manufacturer / TM Owner

ACCORD HEALTHCARE INC

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Methotrexate Subcutaneous 22.5 mg is commonly used for the treatment of certain types of cancer and autoimmune diseases. It works by interfering with the growth of certain cells in the body. People often ask, 'What is Methotrexate used for?' and the answer includes conditions like rheumatoid arthritis and psoriasis, where it helps to reduce inflammation and slow down cell growth.

Side Effects

Common effects of Methotrexate Subcutaneous 22.5 mg may include nausea, fatigue, and mild skin irritation at the injection site. Some users also report temporary hair thinning. These effects vary and are not experienced by everyone.

Precautions & Warnings

Methotrexate Subcutaneous 22.5 mg should be handled with care. It is important to follow the instructions provided by your healthcare professional. Avoid alcohol and ensure regular monitoring of blood counts and liver function.

Avoid Interactions

Methotrexate Subcutaneous 22.5 mg may interact with certain medications, including nonsteroidal anti-inflammatory drugs (NSAIDs) and antibiotics. Always inform your healthcare provider about all medications you are taking to avoid potential interactions.

Frequently Asked Questions

Methotrexate Subcutaneous 22.5 mg is used for the treatment of certain types of cancer and autoimmune diseases, such as rheumatoid arthritis and psoriasis.

Methotrexate Subcutaneous 22.5 mg is administered via subcutaneous injection, typically into the fatty tissue just under the skin.

Common side effects may include nausea, fatigue, and mild skin irritation at the injection site. Some users also report temporary hair thinning.

Methotrexate Subcutaneous 22.5 mg may interact with certain medications, including NSAIDs and antibiotics. Always consult your healthcare provider before combining medications.

Precautions include avoiding alcohol, following healthcare professional instructions, and regular monitoring of blood counts and liver function.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.